title: Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension.
abstract: It has recently been reported that the administration of ketanserin, a serotonin antagonist, was associated with a significant reduction in portal pressure both in portal hypertensive rats and cirrhotic patients. However, this beneficial effect on splanchnic hemodynamics was accompanied by a significant reduction in arterial pressure. Using conscious dogs, we investigated the effect of the chronic oral administration of a new specific antiserotonergic drug, ritanserin (10 mg per day for 5 days), on portal pressure and systemic hemodynamics. Eleven dogs with secondary biliary cirrhosis and portal hypertension due to chronic bile duct ligation were evaluated. One week prior to study, heparinized catheters were placed in the portal vein and brought subcutaneously to the dorsal cervical area. Measurements were made under baseline conditions, following ritanserin administration and 72 hr after the last dose. Ritanserin administration caused a significant reduction in portal pressure (from 17.3 +/- 3.1 mmHg to 13.6 +/- 4.5 mmHg; mean decrease: 23.1%; p less than 0.001). Maximal effects on portal pressure were reached on the fourth day. During the recovery period, hemodynamic parameters returned to baseline values. In six of the 11 cirrhotic dogs with successful chronic catheterization of the inferior vena cava and aorta, ritanserin administration did not cause significant changes in the mean arterial pressure, heart rate, cardiac output and peripheral vascular resistance. These data indicate that chronic implantation of venous and arterial catheters in dogs with secondary biliary cirrhosis is a useful experimental model for pharmacological studies of portal hypertension in conscious animals.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: André-Viallet Clinical Research Center, Hôpital Saint-Luc, Montreal, Quebec, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Mastaï
authors.forename: B
authors.initials: B
authors.lastname: Rocheleau
authors.forename: P M
authors.initials: PM
authors.lastname: Huet
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003135:Common Bile Duct; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006975:Hypertension, Portal / Q000209:etiology / Q000503:physiopathology*; D008026:Ligation; D008105:Liver Cirrhosis, Biliary / Q000209:etiology / Q000503:physiopathology*; D010880:Piperidines / Q000494:pharmacology*; D011169:Portal Vein / Q000503:physiopathology; D016713:Ritanserin; D012702:Serotonin Antagonists; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D010880:Piperidines; D012702:Serotonin Antagonists; D016713:Ritanserin